Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LY3537021
DRUG
3 trials
Sponsors
Eli Lilly and Company
Conditions
Drug-Related Side Effects and Adverse Reactions
Healthy
Nausea
Neoplasms
Type 2 Diabetes Mellitus
Vomiting
Phase 1
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
Completed
NCT04586907
Eli Lilly and Company
Healthy, Type 2 Diabetes Mellitus
Start: 2020-11-23
End: 2021-11-30
Updated: 2021-12-17
A Study of LY3537021 in Healthy Participants
Completed
NCT05444569
Eli Lilly and Company
Healthy
Start: 2022-08-08
End: 2023-02-24
Updated: 2023-03-01
Phase 2
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
Recruiting
NCT07169851
Eli Lilly and Company
Drug-Related Side Effects and Adverse Reactions, Nausea, Neoplasms +1
Start: 2025-11-28
End: 2027-02-01
Target: 204
Updated: 2026-09-04
Related Papers
A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.
Journal of Clinical Oncology
2026-01-10
Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies.
2025-12-12